Women’s Longevity Market Has $350 billion Untapped Potential, Says BCG

The global women’s longevity market could unlock an additional $350 billion in spending by addressing unmet demand, particularly among women going through perimenopause or menopause, according to Boston Consulting Group (BCG).

In its Customer Insights article, The $350 Billion Longevity Mismatch in Women’s Health, BCG said these women were among the most active consumers of longevity products and services, yet also among the least satisfied with available offerings.

The findings draw on BCG’s 2026 Global Study on Longevity, conducted for the St. Moritz Longevity Forum. The survey covered 10,608 respondents across 12 countries, including India, China, Japan, the US, the UK, Germany and France.

Higher spending, unmet needs

Women in perimenopause or menopause spend a median $84 a month on longevity, compared with $68 for women at other life stages and $73 for men, according to BCG.

Around one-third of women in the perimenopause or menopause group said they would be willing to spend more if suitable products or services were available. Among those willing to increase spending, the median additional amount was $108 a month.

“Despite that higher rate of spending, roughly one-third say that they would be willing to spend more—a median incremental amount of USD 108 per month—if the right product or service existed. The market is leaving money on the table,” BCG said.

The consultancy estimated the $350 billion incremental opportunity by applying the additional spending potential to its estimated global population of one billion menopausal women actively engaged in longevity spending.

The figure represents potential additional spending, rather than existing market revenue or confirmed purchases.

More interventions, limited satisfaction

After adjusting for age, BCG found that women in perimenopause or menopause adopted longevity interventions at rates 15–22 percentage points higher than other women or men.

On average, they had tried 3.3 more interventions than women at other life stages and 2.9 more than men.

“Our survey confirms that the mismatch between needs and available offerings is real. Women undergoing perimenopause or menopause transition are the most engaged longevity consumers we surveyed, but also among the least satisfied,” BCG said.

The findings point to a gap between consumers’ willingness to spend and the availability of offerings that meet their needs.

Evidence and access are key

BCG said companies seeking to serve this market would need to establish credibility through evidence-backed products and services, supported by clinical endorsement.

“If companies hope to capture a share of the USD 350 billion opportunity, credibility comes first. A stronger evidence base and real clinical endorsement are the price of entry,” it said.

The report also identified roles for healthcare providers, insurers and employers. Better insurance coverage and employer benefits could improve access to women’s health services while broadening the market for companies addressing these needs.

With inputs from ANI